Surgical Complications After Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer: From Benchmarks to Randomized Clinical Trials

Ann Surg Oncol. 2024 Dec;31(13):8481-8484. doi: 10.1245/s10434-024-16134-7. Epub 2024 Aug 31.

Kjetil Søreide^{1

2

3

4}, Patrik Larsson⁵, Sanjay Pandanaboyana^{6

7}

¹ Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway. ksoreide@mac.com.
² Department of Clinical Medicine, University of Bergen, Bergen, Norway. ksoreide@mac.com.
³ Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway. ksoreide@mac.com.
⁴ Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. ksoreide@mac.com.
⁵ Division of Surgery and Oncology, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
⁶ Hepato-pancreato-biliary and Transplant Unit, Freeman Hospital, Newcastle Upon Tyne, UK.
⁷ Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.

No abstract available

Publication types